- $587.27m
- $634.87m
- $156.85m
- 52
- 19
- 92
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 50.7 | 96 | 234 | 235 | 157 |
Cost of Revenue | |||||
Gross Profit | 31.1 | 61.7 | 116 | 89.7 | 81.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 132 | 171 | 432 | 981 | 313 |
Operating Profit | -81.7 | -75.3 | -197 | -746 | -156 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -81.4 | -74.6 | -208 | -766 | -180 |
Provision for Income Taxes | |||||
Net Income After Taxes | -81.5 | -74.6 | -169 | -764 | -180 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -81.5 | -74.6 | -170 | -769 | -185 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -81.5 | -74.6 | -171 | -769 | -185 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.371 | -0.34 | -0.755 | -1.99 | -0.69 |
Dividends per Share |